|
MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients …
MarketWatch (press release) Patients suffering from acute exacerbations of asthma in the emergency room who were not promptly responding to standard pharmacotherapy were enrolled in the study. MediciNova is currently in the process of auditing and organizing the data and … |
View full post on asthma – Google News